CAMBRIDGE, Mass. -- (Business Wire)
Dicerna
Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of
RNA interference-based therapeutics targeting rare inherited diseases
involving the liver and for cancers that are genetically defined, today
announced that on March 31, 2015, the Compensation Committee of the
Company's Board of Directors approved the grant of inducement stock
options to purchase a total of 24,500 shares of common stock to four new
employees, with all four grants having a grant date of March 31, 2015
(the "Q1 2015 Inducement Grants").
Each of the Q1 2015 Inducement Grants has an exercise price per share
equal to $24.03, the fair market value on the grant date. Each stock
option vests over four years, with 25% vesting on the one-year
anniversary of the employee's first day of employment with the Company
and 1/48 of the shares vesting monthly thereafter, subject to the new
employee's continued service relationship with the Company on each such
date. Each stock option has a ten year term and is subject to the terms
and conditions of the applicable stock option agreement.
Each of the stock options was granted as an inducement material to the
new employees entering into employment with Dicerna Pharmaceuticals,
Inc. in accordance with NASDAQ listing Rule 5635(c)(4).
About Dicerna Pharmaceuticals, Inc.
Dicerna is a biopharmaceutical company focused on the discovery and
development of innovative treatments for rare inherited diseases
involving the liver and for cancers that are genetically defined. The
Company is using its proprietary RNA interference technology platform to
build a broad pipeline in these therapeutic areas. In both rare diseases
and oncology, Dicerna is pursuing targets that have historically been
difficult to inhibit using conventional approaches, but where
connections between targets and diseases are well understood and
documented. The Company intends to discover, develop and commercialize
novel therapeutics either on its own or in collaboration with
pharmaceutical partners. For more information, please visit www.dicerna.com.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statements. Applicable risks and uncertainties include
those relating to our preclinical research and other risks identified
under the heading "Risk Factors" included in our most recent Form 10-K
filing and in other future filings with the SEC. The forward-looking
statements contained in this press release reflect Dicerna's current
views with respect to future events, and Dicerna does not undertake and
specifically disclaims any obligation to update any forward-looking
statements.
Contacts:
Investor Contact:
Westwicke Partners
Peter Vozzo,
443-213-0505
peter.vozzo@westwicke.com
or
Media
Contact:
SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com
Source: Dicerna Pharmaceuticals, Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.